Bayer | Pharmaceuticals’ Post

New research from Technology in Cancer Research & Treatment: Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: A Single Institutional Cohort Study https://lnkd.in/gF5KErVM #cancerresearch #cancertechnology #technology #openaccess #SAGEresearch

Study investigates the targets and related mechanisms of Scutellaria baicalensis for treating non-small cell lung cancer: https://lnkd.in/d6sg7RyC #lungcancer #PharmacolRes #ModernChineseMedicine #Research

📣 Exciting CUTANA CUT&Tag application! Here, EpiCypher pAG-Tn5 and CUT&Tag protocol were used to study localization of cGAS in cancer cells, which helped uncover novel connections between SWI/SNF chromatin remodelers and mTORC2 signaling in chemoresistant colorectal cancer. These results provide promising new strategies for therapeutic development! https://hubs.la/Q02KB1cn0

According to preliminary data presented at #ESMO24, an antitumour activity of telisotuzumab adizutecan (ABBV-400), a c-Met directed antibody-drug conjugate (ADC), was observed in previously treated patients with EGFR wild type (WT) non-squamous non-small cell lung cancer (#NSCLC). To learn more about this topic, read the #ESMODailyReporter article 📌https://ow.ly/vV3J50TCVvR

Learn how a retrospective chart review can provide clinical insights for future treatments in our whitepaper: A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. https://lnkd.in/evaRZpXG #OncologyResearch

Quiz Yourself on the Latest in ROS1+ NSCLC | Applying the Latest Evidence to Guide Treatment of ROS1-Positive Non-Small Cell Lung Cancer | 0.25-hour CME/CE | Booster Quiz | #MedEd #cme #Nonsmallcelllungcancer | https://bit.ly/3BrZ6Yv

Brand new case series report by Alfayea et al. covers "EGFR and ROS-1 co-occurrence in advanced Non-small Cell Lung Cancer" https://lnkd.in/epY_JpFT #EGFR #ROS1 #cooccurrence, #advancedlungadenocarcinoma

We're pushing the boundaries in lung cancer research with our hexavalent OX40 agonist, #INBRX106. INBRX-106 is currently being investigated in a phase 1/2 study as a potential treatment option for Non-Small Cell Lung Cancer, including in IO-refractory patients. Learn more about our ongoing study and our commitment to addressing unmet needs: https://bit.ly/49ZyYks #LungCancer #NSCLC #Inhibrx

The MITOPE clinical trial is looking at a new drug called RSO-021 for fluid around the lung caused by cancer. It is for people who have any type of solid cancer including mesothelioma of the lung. You can read a quick update in this post or visit https://lnkd.in/e5PGfDvx for more information about clinical trials. #clinicaltrials #mitope #mesothelioma #lungcancer

For #TrialTuesday, Haeseong Park, MD, PhD, of Dana-Farber Cancer Institute, lead the Alliance A022102 trial that compares the effect of mFOLFIRINOX versus mFOLFOX with or without nivolumab to treat patients with #metastatic HER2 negative #gastroesophageal cancer. To learn more about this trial, visit https://lnkd.in/g3jFJnRR #NCI #NCTN #gastriccancer